The Interplay of COVID-19 and Hereditary Angioedema: Preventing an Acute Attack.
covid-19
covid-19 pneumonia
hae
hereditary angioedema
icatibant
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
08
08
2022
accepted:
15
09
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Hereditary angioedema (HAE) is a rare inherited disease that is caused by the inactivation of the C1 esterase inhibitor. In this case report, we present a 51-year-old female previously diagnosed with HAE who tested positive for SARS-Cov-2 (COVID-19). The patient was treated symptomatically. Dexamethasone was used to treat COVID-19 pneumonia. Broad-spectrum antibiotics (vancomycin and meropenem) were utilized to prevent future infection. Although the patient did not experience an acute angioedema attack during her hospital stay, the patient expired due to the exacerbation of COVID-19 pneumonia.
Identifiants
pubmed: 36507113
doi: 10.7759/cureus.29189
pmc: PMC9731548
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e29189Informations de copyright
Copyright © 2022, Park et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Allergy Asthma Proc. 2021 Sep 1;42(5):403-408
pubmed: 34474710
Allergy Asthma Proc. 2022 Jan 1;43(1):e1-e10
pubmed: 34983717
Clin Exp Allergy. 2021 Jul;51(7):947-950
pubmed: 33772888
Clin Rev Allergy Immunol. 2019 Apr;56(2):207-218
pubmed: 29909591
Biologics. 2013;7:103-13
pubmed: 23662043
World Allergy Organ J. 2020 Sep;13(9):100454
pubmed: 32834893
J Blood Med. 2015 Apr 16;6:115-23
pubmed: 25931832
Allergy Asthma Proc. 2021 Nov 1;42(6):506-514
pubmed: 34871158
Ann Med. 2016;48(4):256-67
pubmed: 27018196
Allergy Asthma Proc. 2019 Nov 1;40(6):441-445
pubmed: 31690390